ImproMed, LLC. Logo
Issue: 64 - Apr 15, 2014
Growing Your Practice through In-House Management of Mast Cell Tumor Disease
By: AB Science
AB Science

With the continuous shift in the veterinary practice management paradigm, practice owners are finding it necessary to seek new avenues in which to grow their revenue stream by focusing more on offering high quality services versus product sales.

One opportunity that many practice owners are capturing is the in-house treatment of the most prevalent cutaneous malignant neoplasm in dogs, Mast Cell Tumors. Through the medical advancements that introduced tyrosine kinase inhibitors to the arena, veterinarians are now able to offer pet owners another option of treatment to their portfolio, increasing owner compliance while generating more revenue.

At a time that business growth is a concern, the opportunity to increase monthly revenue and value of service is commonly pursued. Now in-house management of an average sized Mast Cell Tumor Disease case can in ring in approximately $790 of revenue per month.

 

 

 

 

 

 

 

For more information on purchasing Kinavet-CA1, contact your local Henry Schein Animal Health representative. For technical information, please call your AB Science field representative or AB Science technical services at 908-273-8700.

**Kinavet-CA1 is conditionally approved by the FDA for the treatment recurrent (post-surgery) or nonresectable Grade II or III cutaneous Mast Cell Tumors in dogs that have not been previously received radiotherapy and/or chemotherapy except corticosteroids.